Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis

被引：40
|
作者：
Cottrell, Mackenzie L. [1 ]
Prince, Heather M. A. [2 ]
Schauer, Amanda P. [1 ]
Sykes, Craig [1 ]
Maffuid, Kaitlyn [1 ]
Poliseno, Amanda [1 ]
Chun, Tae-Wook [3 ]
Huiting, Erin [3 ]
Stanczyk, Frank Z. [4 ]
Peery, Anne F. [5 ]
Dellon, Evan S. [5 ]
Adams, Jessica L. [6 ,7 ]
Gay, Cindy [2 ]
Kashuba, Angela D. M. [1 ,2 ]
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC 27515 USA
[3] NIAID, HIV Immunovirol Unit, 9000 Rockville Pike, Bethesda, MD 20892 USA
[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[5] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA
[6] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA
[7] Cooper Univ Hosp, Early Intervent Program, Camden, NJ USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 12期
基金：
美国国家卫生研究院;
关键词：
transgender; preexposure prophylaxis; lower gastrointestinal tract; HIV; feminizing hormone therapy; HIV; WOMEN; NUCLEOTIDE;
D O I：
10.1093/cid/ciz290
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (rho = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy.
引用
收藏
页码：2201 / 2204
页数：4
相关论文
共 50 条
  • [31] Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study
    Beguelin, Charles
    Friolet, Nicole
    Moradpour, Darius
    Sahli, Roland
    Suter-Riniker, Franziska
    Luthi, Alexander
    Cavassini, Matthias
    Gunthard, Huldrych F.
    Battegay, Manuel
    Bernasconi, Enos
    Schmid, Patrick
    Calmy, Alexandra
    Atkinson, Andrew
    Rauch, Andri
    Wandeler, Gilles
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (09) : 1275 - 1278
  • [32] Assessing the Role of Long-Acting Cabotegravir Preexposure Prophylaxis of Human Immunodeficiency Virus: Opportunities and Aspirations
    Cohen, Myron S.
    Landovitz, Raphael J.
    JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (01): : 1 - 3
  • [33] Abandonment of Human Immunodeficiency Virus Preexposure Prophylaxis Prescriptions at Retail Pharmacies-United States, 2019
    Huang, Ya-Lin A.
    Zhu, Weiming
    Carnes, Neal
    Hoover, Karen W.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (03) : 512 - 514
  • [34] Integrating Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention Into Women's Health Care in the United States
    Seidman, Dominika
    Weber, Shannon
    OBSTETRICS AND GYNECOLOGY, 2016, 128 (01): : 37 - 43
  • [35] No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis
    Patel, Nimish
    Morris, Sheldon
    Burke, Leah
    Chow, Karen
    Pacheco, Deedee
    Anderson, Peter
    Stancyzk, Frank
    Blumenthal, Jill
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (10) : 2360 - 2365
  • [36] Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study
    Grant, Robert M.
    Mannheimer, Sharon
    Hughes, James P.
    Hirsch-Moverman, Yael
    Loquere, Avelino
    Chitwarakorn, Anupong
    Curlin, Marcel E.
    Li, Maoji
    Amico, K. Rivet
    Hendrix, Craig W.
    Anderson, Peter L.
    Dye, Bonnie J.
    Marzinke, Mark A.
    Piwowar-Manning, Estelle
    McKinstry, Laura A.
    Elharrar, Vanessa
    Stirratt, Michael
    Rooney, James F.
    Eshleman, Susan H.
    McNicholl, Janet M.
    van Griensven, Frits
    Holtz, Timothy H.
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (11) : 1712 - 1721
  • [37] Human Immunodeficiency Virus Preexposure Prophylaxis Awareness and Acceptability among Men Who Have Sex with Men and Transgender Persons in India: Systematic Review and Meta-analysis
    Sethi, Adhish Kumar
    Haldar, Partha
    Kant, Shashi
    Rai, Sanjay Kumar
    Rajan, Shobini
    Kumar, Parveen
    INDIAN JOURNAL OF PUBLIC HEALTH, 2024, 68 (02) : 251 - +
  • [38] Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections
    Castillo-Mancilla, Jose R.
    Morrow, Mary
    Coyle, Ryan P.
    Coleman, Stacey S.
    Gardner, Edward M.
    Zheng, Jia-Hua
    Ellison, Lucas
    Bushman, Lane R.
    Kiser, Jennifer J.
    Mawhinney, Samantha
    Anderson, Peter L.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (08) : 1335 - 1342
  • [39] Moving Forward With Treatment of Gonorrhea for Users of Human Immunodeficiency Virus Preexposure Prophylaxis Given the Threat of Antimicrobial Resistance
    Jenness, Samuel M.
    Weiss, Kevin M.
    Goodreau, Steven M.
    Gift, Thomas
    Chesson, Harrell
    Hoover, Karen W.
    Smith, Dawn K.
    Liu, Albert Y.
    Sullivan, Patrick S.
    Rosenberg, Eli S.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (01) : 155 - 156
  • [40] Worsening Disparities in State-Level Uptake of Human Immunodeficiency Virus Preexposure Prophylaxis, 2014-2018
    Powers, Samuel D.
    McQuade, Elizabeth T. Rogawski
    Killelea, Amy
    Horn, Tim
    McManus, Kathleen A.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07):
12345